Last 12 months
Inside the activity.
1 purchase rows · 60 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 2 |
| Dec 2025 | 1 | 6 |
| Jan 2026 | 0 | 3 |
| Feb 2026 | 0 | 3 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 8 |
| May 2026 | 0 | 7 |
| Jun 2026 | 0 | 10 |
| Jul 2026 | 0 | 12 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 5 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2025 Filed Apr 3, 2025 20:48 UTC |
Barnett Eva ReneeChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 125,180 | $0.00 Strike: $15.20 | $0.00 |
DisclosureSEC source: 0001764013-25-000051 · wk-form4_1743713294.xml · derivative · entry 2 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,180 Underlying: Common Stock · 125,180 shares Expires 2035-04-01 F2 · derivative.exercise_date: The shares underlying the options will vest as to 25% of the shares on April 1, 2026 and the remainder will vest in 36 substantially equal monthly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:48 UTC |
Barnett Eva ReneeChief Financial Officer
|
GrantCommon Stock | 88,878 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-25-000051 · wk-form4_1743713294.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 410,830 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the units on April 1, 2026, and the remainder will vest in substantially equal installments on a quarterly basis over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:46 UTC |
Salzmann PeterDirector · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 374,395 | $0.00 Strike: $15.20 | $0.00 |
DisclosureSEC source: 0001764013-25-000049 · wk-form4_1743713207.xml · derivative · entry 2 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 374,395 Underlying: Common Stock · 374,395 shares Expires 2035-04-01 F2 · derivative.exercise_date: The shares underlying the options will vest as to 25% of the shares on April 1, 2026 and the remainder will vest in 36 substantially equal monthly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:46 UTC |
Salzmann PeterDirector · Chief Executive Officer
|
GrantCommon Stock | 265,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-25-000049 · wk-form4_1743713207.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,214,606 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the units on April 1, 2026, and the remainder will vest in substantially equal installments on a quarterly basis over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:44 UTC |
Pande AtulDirector
|
GrantStock Option (right to buy) · Derivative | 7,600 | $0.00 Strike: $15.20 | $0.00 |
DisclosureSEC source: 0001764013-25-000047 · wk-form4_1743713068.xml · derivative · entry 3 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,600 Underlying: Common Stock · 7,600 shares Expires 2035-04-01 F2 · derivative.exercise_date: The shares underlying the options will vest on April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:44 UTC |
Pande AtulDirector
|
GrantCommon Stock | 16,188 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-25-000047 · wk-form4_1743713068.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,851 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:41 UTC |
Fromkin Andrew J.Director
|
GrantStock Option (right to buy) · Derivative | 7,600 | $0.00 Strike: $15.20 | $0.00 |
DisclosureSEC source: 0001764013-25-000043 · wk-form4_1743712868.xml · derivative · entry 2 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,600 Underlying: Common Stock · 7,600 shares Expires 2035-04-01 F2 · derivative.exercise_date: The shares underlying the options will vest on April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:41 UTC |
Fromkin Andrew J.Director
|
GrantCommon Stock | 16,188 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-25-000043 · wk-form4_1743712868.xml · nonDerivative · entry 1 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,101 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:37 UTC |
Torti FrankDirector
|
GrantStock Option (right to buy) · Derivative | 93,599 | $0.00 Strike: $15.20 | $0.00 |
DisclosureSEC source: 0001764013-25-000039 · wk-form4_1743712656.xml · derivative · entry 2 Torti Frank · CIK 0001647805 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,599 Underlying: Common Stock · 93,599 shares Expires 2035-04-01 F2 · derivative.exercise_date: The shares underlying the options will vest in substantially equal quarterly installments over two years measured from the date of the award, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:37 UTC |
Torti FrankDirector
|
GrantCommon Stock | 199,365 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-25-000039 · wk-form4_1743712656.xml · nonDerivative · entry 1 Torti Frank · CIK 0001647805 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 835,039 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. These units will vest in equal quarterly installments over two years measured from the date of the award, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:43 UTC |
Hughes Douglas J.Director
|
GrantStock Option (right to buy) · Derivative | 7,600 | $0.00 Strike: $15.20 | $0.00 |
DisclosureSEC source: 0001764013-25-000045 · wk-form4_1743712974.xml · derivative · entry 2 Hughes Douglas J. · CIK 0001710863 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,600 Underlying: Common Stock · 7,600 shares Expires 2035-04-01 F2 · derivative.exercise_date: The shares underlying the options will vest on April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:43 UTC |
Hughes Douglas J.Director
|
GrantCommon Stock | 16,188 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-25-000045 · wk-form4_1743712974.xml · nonDerivative · entry 1 Hughes Douglas J. · CIK 0001710863 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,773 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 20:18 UTC |
Fromkin Andrew J.Director
|
SaleCommon Stock | 1,384 | $19.96 | $27,624.64 |
DisclosureSEC source: 0001764013-25-000034 · wk-form4_1741724319.xml · nonDerivative · entry 2 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,913 F1 · shares: The sale of shares of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2024 in order to satisfy applicable tax obligations arising in connection with the vesting and deferred settlement of a prior award of restricted stock units. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.91 - $20.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 20:18 UTC |
Fromkin Andrew J.Director
|
SaleCommon Stock | 6,616 | $19.52 | $129,144.32 |
DisclosureSEC source: 0001764013-25-000034 · wk-form4_1741724319.xml · nonDerivative · entry 1 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,297 F1 · shares: The sale of shares of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2024 in order to satisfy applicable tax obligations arising in connection with the vesting and deferred settlement of a prior award of restricted stock units. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.91 - $19.86 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 16:06 UTC |
Macias William L.Chief Medical Officer
|
SaleCommon Stock | 2,055 | $20.86 | $42,867.30 |
DisclosureSEC source: 0001764013-25-000032 · wk-form4_1740171953.xml · nonDerivative · entry 1 Macias William L. · CIK 0001864280 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 357,353 F1 · shares: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on February 17, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.51 - $21.09 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 21:05 UTC |
Barnett Eva ReneeChief Financial Officer
|
SaleCommon Stock | 2,814 | $20.86 | $58,700.04 |
DisclosureSEC source: 0001764013-25-000031 · wk-form4_1740171904.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 321,952 F1 · shares: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on February 17, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.51 - $21.09 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 21:04 UTC |
Salzmann PeterDirector · Chief Executive Officer
|
SaleCommon Stock | 15,439 | $20.86 | $322,057.54 |
DisclosureSEC source: 0001764013-25-000030 · wk-form4_1740171852.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 948,786 F1 · shares: On August 17, 2022, the holder was granted 451,264 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 28,204 of these RSUs vested on February 17, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.51 - $21.09 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 22, 2025 Filed Jan 24, 2025 16:22 UTC |
Geffner MichaelChief Medical Officer
|
SaleCommon Stock | 2,657 | $23.59 | $62,678.63 |
DisclosureSEC source: 0001764013-25-000018 · wk-form4_1737753717.xml · nonDerivative · entry 1 Geffner Michael · CIK 0002007249 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,314 F1 · shares: On January 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 3 filed on January 16, 2024, of which 6,250 of these RSUs vested on January 17, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| January 22, 2025 Filed Jan 24, 2025 21:23 UTC |
Stout Jay SChief Technology Officer
|
SaleCommon Stock | 2,195 | $23.59 | $51,780.05 |
DisclosureSEC source: 0001764013-25-000019 · wk-form4_1737753791.xml · nonDerivative · entry 1 Stout Jay S · CIK 0001702969 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,991 F1 · shares: On April 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 19, 2023, of which 6,250 of these RSUs vested on January 17, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 16:07 UTC |
Macias William L.Chief Medical Officer
|
SaleCommon Stock | 19 | $24.19 | $459.61 |
DisclosureSEC source: 0001764013-25-000015 · wk-form4_1737148045.xml · nonDerivative · entry 4 Macias William L. · CIK 0001864280 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 359,408 F4 · shares: On June 11, 2021, the holder was granted 18,674 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on June 15, 2021, of which 1,167 of these RSUs vested on January 13, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.13 - $24.21 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 16:07 UTC |
Macias William L.Chief Medical Officer
|
SaleCommon Stock | 387 | $23.81 | $9,214.47 |
DisclosureSEC source: 0001764013-25-000015 · wk-form4_1737148045.xml · nonDerivative · entry 3 Macias William L. · CIK 0001864280 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 359,427 F4 · shares: On June 11, 2021, the holder was granted 18,674 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on June 15, 2021, of which 1,167 of these RSUs vested on January 13, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.13 - $24.07 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 16:07 UTC |
Macias William L.Chief Medical Officer
|
SaleCommon Stock | 94 | $24.19 | $2,273.86 |
DisclosureSEC source: 0001764013-25-000015 · wk-form4_1737148045.xml · nonDerivative · entry 2 Macias William L. · CIK 0001864280 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 359,814 F1 · shares: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on January 12, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.13 - $24.21 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 16:07 UTC |
Macias William L.Chief Medical Officer
|
SaleCommon Stock | 1,883 | $23.81 | $44,834.23 |
DisclosureSEC source: 0001764013-25-000015 · wk-form4_1737148045.xml · nonDerivative · entry 1 Macias William L. · CIK 0001864280 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 359,908 F1 · shares: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on January 12, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.13 - $24.07 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:05 UTC |
Barnett Eva ReneeChief Financial Officer
|
SaleCommon Stock | 109 | $24.19 | $2,636.71 |
DisclosureSEC source: 0001764013-25-000014 · wk-form4_1737147952.xml · nonDerivative · entry 2 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 324,766 F1 · shares: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on January 12, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.13 - $24.21 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:05 UTC |
Barnett Eva ReneeChief Financial Officer
|
SaleCommon Stock | 2,189 | $23.81 | $52,120.09 |
DisclosureSEC source: 0001764013-25-000014 · wk-form4_1737147952.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 324,875 F1 · shares: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on January 12, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.13 - $24.07 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:04 UTC |
Salzmann PeterDirector · Chief Executive Officer
|
SaleCommon Stock | 415 | $24.19 | $10,038.85 |
DisclosureSEC source: 0001764013-25-000013 · wk-form4_1737147867.xml · nonDerivative · entry 2 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 964,225 F1 · shares: On April 12, 2023, the holder was granted 243,832 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 15,239 of these RSUs vested on January 12, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.13 - $24.21 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:04 UTC |
Salzmann PeterDirector · Chief Executive Officer
|
SaleCommon Stock | 8,352 | $23.81 | $198,861.12 |
DisclosureSEC source: 0001764013-25-000013 · wk-form4_1737147867.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 964,640 F1 · shares: On April 12, 2023, the holder was granted 243,832 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 15,239 of these RSUs vested on January 12, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.13 - $24.07 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 13, 2025 Filed Jan 15, 2025 21:36 UTC |
Roivant Sciences Ltd.Director · 10% owner
|
PurchaseCommon Stock, $0.0001 par value per share | 16,845,010 | $20.00 | $336,900,200.00 |
DisclosureSEC source: 0001140361-25-001188 · form4.xml · nonDerivative · entry 1 Roivant Sciences Ltd. · CIK 0001635088 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,650,341 Read SEC document |
| January 08, 2025 Filed Jan 10, 2025 21:12 UTC |
Barnett Eva ReneeChief Financial Officer
|
SaleCommon Stock | 4,105 | $24.10 | $98,930.50 |
DisclosureSEC source: 0001764013-25-000004 · wk-form4_1736543549.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 327,064 F1 · shares: On October 15, 2021, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 18, 2021, of which 8,937 of these RSUs vested on January 4, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.91 - $24.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 08, 2025 Filed Jan 10, 2025 21:11 UTC |
Salzmann PeterDirector · Chief Executive Officer
|
SaleCommon Stock | 5,105 | $24.10 | $123,030.50 |
DisclosureSEC source: 0001764013-25-000003 · wk-form4_1736543457.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 972,992 F1 · shares: On March 19, 2021, the holder was granted 132,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 8,282 of these RSUs vested on January 1, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.91 - $24.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 22:02 UTC |
Van Tuyl ChristopherChief Legal Officer
|
GrantStock Option (right to buy) · Derivative | 137,446 | $0.00 Strike: $27.63 | $0.00 |
DisclosureSEC source: 0001764013-24-000204 · wk-form4_1734559363.xml · derivative · entry 2 Van Tuyl Christopher · CIK 0001779707 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,446 Underlying: Common Stock · 137,446 shares Expires 2034-12-16 F2 · derivative.exercise_date: This option was granted pursuant to the Issuer's 2019 Equity Incentive Plan. The shares underlying the option will vest as to 25% of the shares on December 16, 2025, and the remainder will vest in 12 successive substantially equal quarterly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 22:02 UTC |
Van Tuyl ChristopherChief Legal Officer
|
GrantCommon Stock | 109,956 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-24-000204 · wk-form4_1734559363.xml · nonDerivative · entry 1 Van Tuyl Christopher · CIK 0001779707 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,956 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the units on December 16, 2025, and the remainder will vest in 12 successive substantially equal quarterly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 21:22 UTC |
Pande AtulDirector
|
SaleCommon Stock | 7,750 | $28.54 | $221,185.00 |
DisclosureSEC source: 0001764013-24-000200 · wk-form4_1733347352.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,663 F1 · shares: The sale of shares of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 24, 2023 in order to satisfy applicable tax obligations arising in connection with the vesting and deferred settlement of a prior award of restricted stock units. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.03 - $29.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 21:20 UTC |
Hughes Douglas J.Director
|
SaleCommon Stock | 5,425 | $28.54 | $154,829.50 |
DisclosureSEC source: 0001764013-24-000199 · wk-form4_1733347209.xml · nonDerivative · entry 1 Hughes Douglas J. · CIK 0001710863 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,585 F1 · shares: The sale of shares of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2023 in order to satisfy applicable tax obligations arising in connection with the vesting and deferred settlement of a prior award of restricted stock units. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.05 - $28.99 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 16:11 UTC |
Macias William L.Chief Medical Officer
|
SaleCommon Stock | 3,353 | $25.45 | $85,333.85 |
DisclosureSEC source: 0001764013-24-000195 · wk-form4_1732309904.xml · nonDerivative · entry 1 Macias William L. · CIK 0001864280 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 361,791 F1 · shares: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on November 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.91 - $25.81 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 21:09 UTC |
Barnett Eva ReneeChief Financial Officer
|
SaleCommon Stock | 4,174 | $25.45 | $106,228.30 |
DisclosureSEC source: 0001764013-24-000194 · wk-form4_1732309782.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 331,169 F1 · shares: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on November 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.91 - $25.81 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 21:12 UTC |
Levine Mark S.Chief Legal Officer
|
SaleCommon Stock | 3,650 | $25.45 | $92,892.50 |
DisclosureSEC source: 0001764013-24-000196 · wk-form4_1732309949.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 319,228 F1 · shares: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on November 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.91 - $25.81 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 21:08 UTC |
Salzmann PeterDirector · Chief Executive Officer
|
SaleCommon Stock | 16,692 | $25.45 | $424,811.40 |
DisclosureSEC source: 0001764013-24-000193 · wk-form4_1732309693.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 978,097 F1 · shares: On August 17, 2022, the holder was granted 451,264 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 28,204 of these RSUs vested on November 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.91 - $25.81 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 22:15 UTC |
Gloria MelanieChief Operating Officer
|
GrantStock Option (right to buy) · Derivative | 137,446 | $0.00 Strike: $25.51 | $0.00 |
DisclosureSEC source: 0001764013-24-000188 · wk-form4_1732140934.xml · derivative · entry 2 Gloria Melanie · CIK 0001973838 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,446 Underlying: Common Stock · 137,446 shares Expires 2034-11-18 F2 · derivative.exercise_date: This option was granted pursuant to the Issuer's 2019 Equity Incentive Plan. The shares underlying the option will vest as to 25% of the shares on November 18, 2025, and the remainder will vest in 12 successive substantially equal quarterly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 22:15 UTC |
Gloria MelanieChief Operating Officer
|
GrantCommon Stock | 109,956 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-24-000188 · wk-form4_1732140934.xml · nonDerivative · entry 1 Gloria Melanie · CIK 0001973838 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,956 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the units on November 18, 2025, and the remainder will vest in 12 successive substantially equal quarterly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| October 23, 2024 Filed Oct 25, 2024 16:23 UTC |
Geffner MichaelChief Medical Officer
|
SaleCommon Stock | 3,189 | $29.53 | $94,171.17 |
DisclosureSEC source: 0001764013-24-000179 · wk-form4_1729887814.xml · nonDerivative · entry 1 Geffner Michael · CIK 0002007249 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,971 F1 · shares: On January 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 3 filed on January 16, 2024, of which 6,250 of these RSUs vested on October 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.38 - $29.68 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 23, 2024 Filed Oct 25, 2024 20:21 UTC |
Stout Jay SChief Technology Officer
|
SaleCommon Stock | 2,740 | $29.53 | $80,912.20 |
DisclosureSEC source: 0001764013-24-000178 · wk-form4_1729887693.xml · nonDerivative · entry 1 Stout Jay S · CIK 0001702969 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,186 F1 · shares: On April 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 19, 2023, of which 6,250 of these RSUs vested on October 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.38 - $29.68 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 23, 2024 Filed Oct 25, 2024 20:25 UTC |
Levine Mark S.Chief Legal Officer
|
SaleCommon Stock | 4,361 | $29.53 | $128,780.33 |
DisclosureSEC source: 0001764013-24-000180 · wk-form4_1729887897.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 322,878 F1 · shares: On January 28, 2022, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on January 31, 2022, of which 8,937 of these RSUs vested on October 19, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.38 - $29.68 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 16:30 UTC |
Macias William L.Chief Medical Officer
|
SaleCommon Stock | 561 | $28.79 | $16,151.19 |
DisclosureSEC source: 0001764013-24-000173 · wk-form4_1729283415.xml · nonDerivative · entry 2 Macias William L. · CIK 0001864280 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 365,144 F3 · shares: On June 11, 2021, the holder was granted 18,674 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on June 15, 2021, of which 1,167 of these RSUs vested on October 13, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.31 - $29.14 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 16:30 UTC |
Macias William L.Chief Medical Officer
|
SaleCommon Stock | 2,627 | $28.79 | $75,631.33 |
DisclosureSEC source: 0001764013-24-000173 · wk-form4_1729283415.xml · nonDerivative · entry 1 Macias William L. · CIK 0001864280 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 365,705 F1 · shares: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on October 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.31 - $29.14 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 20:31 UTC |
Salzmann PeterDirector · Chief Executive Officer
|
SaleCommon Stock | 9,095 | $28.79 | $261,845.05 |
DisclosureSEC source: 0001764013-24-000174 · wk-form4_1729283466.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 994,789 F1 · shares: On April 12, 2023, the holder was granted 243,832 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 15,240 of these RSUs vested on October 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.31 - $29.14 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 20:28 UTC |
Levine Mark S.Chief Legal Officer
|
SaleCommon Stock | 2,860 | $28.79 | $82,339.40 |
DisclosureSEC source: 0001764013-24-000172 · wk-form4_1729283330.xml · nonDerivative · entry 1 Levine Mark S. · CIK 0001617236 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 327,239 F1 · shares: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on October 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.31 - $29.14 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 20:27 UTC |
Barnett Eva ReneeChief Financial Officer
|
SaleCommon Stock | 3,271 | $28.79 | $94,172.09 |
DisclosureSEC source: 0001764013-24-000171 · wk-form4_1729283253.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 335,343 F1 · shares: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on October 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.31 - $29.14 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 09, 2024 Filed Oct 11, 2024 20:04 UTC |
Barnett Eva ReneeChief Financial Officer
|
SaleCommon Stock | 5,162 | $29.56 | $152,588.72 |
DisclosureSEC source: 0001764013-24-000166 · wk-form4_1728677055.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 338,614 F1 · shares: On October 15, 2021, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 18, 2021, of which 8,938 of these RSUs vested on October 4, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.28 - $29.85 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 09, 2024 Filed Oct 11, 2024 20:02 UTC |
Salzmann PeterDirector · Chief Executive Officer
|
SaleCommon Stock | 4,460 | $29.56 | $131,837.60 |
DisclosureSEC source: 0001764013-24-000165 · wk-form4_1728676955.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,003,884 F1 · shares: On March 19, 2021, the holder was granted 132,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 8,281 of these RSUs vested on October 1, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.28 - $29.85 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.